Do you want to read an article? Please log in or register.
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
Lung Cancer
RECOMMENDED
Related content
Lung Cancer
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study
Oncol Ther
Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N
doi: 10.1007/s40487-026-00437-8
RECOMMENDED
Lung Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Lung Cancer
Real-World Outcomes of First-Line Pembrolizumab-Based Therapy in Advanced Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study
J Clin Med
Koren E, Yaacov A, Zidan J, C Roisman L, Peled N, Asna N
doi: 10.3390/jcm15124757
RECOMMENDED
Lung Cancer
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A
doi: 10.1016/j.cllc.2025.12.007
RECOMMENDED
Lung Cancer
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
J Clin Med
Veccia A, D'Argento E, Morgillo F, Pizzutilo EG, Vitiello F, Pavan A, Lombardo F, Russano M, Morabito A, Gariazzo E, Genova C, Chiari R, Cristofano A, Delconte A, Vattemi E, Dessi A, Galanti D, Busato S, Palazzolo G, Savastano C, Azzarello G, Verderame F, Mazzi C, Bencardino D, Dipasquale M, Scala A, Della Corte CM, Piscazzi D, Gilli M, Bria E, Caffo O, Gori S, Inno A
doi: 10.3390/jcm15031165
Lung Cancer
Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
J Clin Med
Yue H, Zhou Q, Wang S, Li S, Li J, La H, Meng S
doi: 10.3390/jcm15176749
Lung Cancer
Real-life management and outcomes of octogenarians with non-small-cell lung cancer: A 10-year evolution
Eur J Cancer
Corre R, Monnet I, Moreau L, Pinsolle J, Hominal S, Campana M, Chikouche R, Slaouti P, Tavernier JY, Clarot C, Kuntz P, Fouet K, Rabut H, Dehette S, Thirard L, Paysse M, Nunes D, Letierce A, Morel H, Debieuvre D, Study Group KBP-2020-CPHG
doi: 10.1016/j.ejca.2026.116845
Lung Cancer
Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England
Lung Cancer
Karim N, Arnold K, Summers Y, Akram T, Trankov N, Vladimirova A, Chopra D, Mesa-Frias M, Waterhouse D, Stollenwerk B
doi: 10.1016/j.lungcan.2026.109469
Lung Cancer
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L
Clin Lung Cancer
Kataoka S, Shukuya T, Ohtsu H, Miyawaki T, Fujimoto D, Hayashi H, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Otsubo K, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Yamamoto N, Okamoto I, Takahashi K
doi: 10.1016/j.cllc.2025.12.002